These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 21426260)

  • 1. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.
    McMahon M; Hahn BH; Skaggs BJ
    Expert Rev Clin Immunol; 2011 Mar; 7(2):227-41. PubMed ID: 21426260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on cardiovascular disease in lupus.
    Lewandowski LB; Kaplan MJ
    Curr Opin Rheumatol; 2016 Sep; 28(5):468-76. PubMed ID: 27227346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.
    Kahlenberg JM; Kaplan MJ
    Arthritis Res Ther; 2011 Feb; 13(1):203. PubMed ID: 21371346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease in systemic lupus erythematosus: an update.
    Liu Y; Kaplan MJ
    Curr Opin Rheumatol; 2018 Sep; 30(5):441-448. PubMed ID: 29870498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention.
    Kostopoulou M; Nikolopoulos D; Parodis I; Bertsias G
    Curr Vasc Pharmacol; 2020; 18(6):549-565. PubMed ID: 31880245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus.
    Gustafsson JT; Svenungsson E
    Autoimmunity; 2014 Mar; 47(2):67-76. PubMed ID: 24228980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular co-morbidity in rheumatic diseases.
    Turesson C; Jacobsson LT; Matteson EL
    Vasc Health Risk Manag; 2008; 4(3):605-14. PubMed ID: 18827910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus.
    Jordan N; Lutalo PM; D'Cruz DP
    Immunotherapy; 2015; 7(3):255-70. PubMed ID: 25804478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherosclerotic vascular disease in the autoimmune rheumatologic patient.
    Mankad R
    Curr Atheroscler Rep; 2015 Apr; 17(4):497. PubMed ID: 25721102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory lipids as a target for therapy in the rheumatic diseases.
    McMahon M; Brahn E
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1213-24. PubMed ID: 18616417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.
    Al Gadban MM; Alwan MM; Smith KJ; Hammad SM
    Clin Immunol; 2015 Apr; 157(2):133-44. PubMed ID: 25638414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.
    Bakshi J; Segura BT; Wincup C; Rahman A
    Clin Rev Allergy Immunol; 2018 Dec; 55(3):352-367. PubMed ID: 28853005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk factors of thickened intima-media and atherosclerotic plaque development in carotid arteries in patients with systemic lupus erythematosus].
    Fischer K
    Ann Acad Med Stetin; 2008; 54(2):22-32. PubMed ID: 19374227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human low-affinity IgG receptor FcγRIIA polymorphism H131R associates with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus.
    Clancy R; El Bannoudi H; Rasmussen SE; Bornkamp N; Allen N; Dann R; Reynolds H; Buyon JP; Berger JS
    J Thromb Haemost; 2019 Mar; 17(3):532-537. PubMed ID: 30638300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus.
    Anania C; Gustafsson T; Hua X; Su J; Vikström M; de Faire U; Heimbürger M; Jogestrand T; Frostegård J
    Arthritis Res Ther; 2010; 12(6):R214. PubMed ID: 21092251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus.
    Manzi S; Selzer F; Sutton-Tyrrell K; Fitzgerald SG; Rairie JE; Tracy RP; Kuller LH
    Arthritis Rheum; 1999 Jan; 42(1):51-60. PubMed ID: 9920014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular disease in systemic lupus erythematosus: has the time for action come?
    van Leuven SI; Kastelein JJ; Hayden MR; d'Cruz D; Hughes GR; Stroes ES
    Curr Opin Lipidol; 2005 Oct; 16(5):501-6. PubMed ID: 16148533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction and management of cardiovascular outcomes in systemic lupus erythematosus.
    Frostegård J
    Expert Rev Clin Immunol; 2015 Feb; 11(2):247-53. PubMed ID: 25517760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell activating factor and related genetic variants in lupus related atherosclerosis.
    Theodorou E; Nezos A; Antypa E; Ioakeimidis D; Koutsilieris M; Tektonidou M; Moutsopoulos HM; Mavragani CP
    J Autoimmun; 2018 Aug; 92():87-92. PubMed ID: 29859654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Birth control in women with lupus and other high-risk groups: do we need a paradigm shift?
    Gompel A
    Joint Bone Spine; 2006 Oct; 73(5):485-7. PubMed ID: 16928461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.